Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12110081 | 0.84 | CXCR3 (0.30) | CXCR3 | |
| SCHEMBL12333012 | 0.82 | ESR2 (0.35) | — | |
| SCHEMBL12110085 | 0.82 | — | — | |
| SCHEMBL12110153 | 0.81 | TDP1 (0.32) | CXCR3LMNASMN1; SMN2 | |
| SCHEMBL12110145 | 0.78 | CHRM1 (0.35) | — | |
| SCHEMBL12110391 | 0.75 | GRIN1 (0.34) | — | |
| SCHEMBL14641847 | 0.74 | TDP1 (0.32) | CXCR3LMNASMN1; SMN2 | |
| SCHEMBL12107822 | 0.70 | BACE1 (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL14562829 | 0.69 | CHRM2 (0.32) | — | |
| SCHEMBL12332999 | 0.68 | ESR2 (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | CXCR3 2415/4885LMNA 1265/4885SMN1; SMN2 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.